Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multi-centre, Randomised, Double Blind, Placebo-controlled, Parallel, Phase III Study to Assess the Safety, Tolerability and Efficacy of Bilastine Ophthalmic Solution 0.6% in Children

NCT04810390 is registered in ClinicalTrials.gov with Faes Farma, S.A. as lead sponsor.

NCT NCT04810390
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04810390 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multi-centre, Randomised, Double Blind, Placebo-controlled, Parallel, Phase III Study to Assess the Safety, Tolerability and Efficacy of Bilastine Ophthalmic Solution 0.6% in Children
Lead sponsor
Faes Farma, S.A.
Phase
Phase 3
Overall status
Completed
Start date
March 26, 2021
Completion date
November 30, 2022
Enrollment
59 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

allergic conjunctivitis